share_log

利特米:截至二零二四年十二月三十一日止財政年度之年度業績公告

RITAMIX: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

HKEX ·  Mar 28 14:37

Summary by Moomoo AI

利特米有限公司2024財年收入同比增長4%至1.23億令吉,毛利微降1.3%至2,577萬令吉。純利下跌30.2%至768萬令吉,每股盈利為1.76令吉仙。董事會已批准派發特別股息每股0.11港元,總額約5,134萬港元。收入增長主要來自分銷業務,該業務收入增長13.5%至9,478萬令吉,主要受惠於成功取得新銷售合約及現有客戶需求增加。然而,製造業務收入因維生素和礦物質預混料產品價格競爭激烈,下跌19%至2,776萬令吉。展望未來,公司將繼續推進新生產工廠建設、設立新測試實驗室等擴張計劃,並積極探索合適的業務及投資機會。管理層表示將密切監察全球經濟形勢,審慎評估資金使用時機,預計未動用上市募集資金將於2026年12月31日前悉數動用。
利特米有限公司2024財年收入同比增長4%至1.23億令吉,毛利微降1.3%至2,577萬令吉。純利下跌30.2%至768萬令吉,每股盈利為1.76令吉仙。董事會已批准派發特別股息每股0.11港元,總額約5,134萬港元。收入增長主要來自分銷業務,該業務收入增長13.5%至9,478萬令吉,主要受惠於成功取得新銷售合約及現有客戶需求增加。然而,製造業務收入因維生素和礦物質預混料產品價格競爭激烈,下跌19%至2,776萬令吉。展望未來,公司將繼續推進新生產工廠建設、設立新測試實驗室等擴張計劃,並積極探索合適的業務及投資機會。管理層表示將密切監察全球經濟形勢,審慎評估資金使用時機,預計未動用上市募集資金將於2026年12月31日前悉數動用。
RITAMIX Limited's revenue for the fiscal year 2024 grew by 4% year-on-year to 0.123 billion ringgit, with gross profit slightly decreasing by 1.3% to 25.77 million ringgit. Net profit fell by 30.2% to 7.68 million ringgit, with earnings per share at 1.76 sen. The Board of Directors has approved a special dividend of 0.11 Hong Kong dollars per share, totaling approximately 51.34 million Hong Kong dollars.The revenue growth was mainly driven by the distribution business, which saw a 13.5% increase in revenue to 94.78 million ringgit, primarily benefiting from successfully securing new sales contracts and increased demand from existing customers. However, revenue from the manufacturing business fell by 19% to 27.76 million ringgit due to intense price competition in Vitamins and mineral premix products.Looking ahead, the company will continue...Show More
RITAMIX Limited's revenue for the fiscal year 2024 grew by 4% year-on-year to 0.123 billion ringgit, with gross profit slightly decreasing by 1.3% to 25.77 million ringgit. Net profit fell by 30.2% to 7.68 million ringgit, with earnings per share at 1.76 sen. The Board of Directors has approved a special dividend of 0.11 Hong Kong dollars per share, totaling approximately 51.34 million Hong Kong dollars.The revenue growth was mainly driven by the distribution business, which saw a 13.5% increase in revenue to 94.78 million ringgit, primarily benefiting from successfully securing new sales contracts and increased demand from existing customers. However, revenue from the manufacturing business fell by 19% to 27.76 million ringgit due to intense price competition in Vitamins and mineral premix products.Looking ahead, the company will continue to advance plans for new production facility construction and establish new testing laboratories as part of its expansion strategy, while actively exploring suitable business and investment opportunities. Management stated that it will closely monitor the global economic situation and prudently assess the timing of capital usage, expecting that unutilized funds raised from the listing will be fully utilized before December 31, 2026.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 398

Recommended

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.